Who is sponsoring NCT05619328?

NCT05619328 is sponsored by Procter and Gamble.

What drugs are being tested in NCT05619328?

Interventions in NCT05619328: Vitamin B combination tablet, Placebo Tablet.

What condition does NCT05619328 study?

NCT05619328 studies Peripheral Sensory Neuropathy of Different Etiologies.

Is NCT05619328 still recruiting?

NCT05619328 is currently completed. Last updated 28 November 2023.

Last reviewed 2023-11-28 · How we verify

NCT05619328

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Prospective Clinical Trial to Evaluate the Efficacy and Safety of Neurotropic B-Vitamins in Clinically Diagnosed Peripheral Sensory Polyneuropathy of Different Etiologies.

Completed Phase 3 Last updated 28 November 2023

What this trial tests

Phase 3 trial testing Vitamin B combination tablet in Peripheral Sensory Neuropathy of Different Etiologies in 323 participants. Completed in 2 November 2023.

Timeline

6 September 2022

Primary endpoint
2 November 2023

2 November 2023

Quick facts

Lead sponsor	Procter and Gamble
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	323
Start date	6 September 2022
Primary completion	2 November 2023
Estimated completion	2 November 2023
Sites	1 location across Mexico

Drugs / interventions tested

Vitamin B combination tablet
Placebo Tablet

Conditions studied

Peripheral Sensory Neuropathy of Different Etiologies — all drugs for Peripheral Sensory Neuropathy of Different Etiologies →

Sponsor

Procter and Gamble — full company profile →

Who can join

Adults 18 to 70, any sex, with Peripheral Sensory Neuropathy of Different Etiologies. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is designed to investigate the efficacy of the Test Product in subjects with clinically diagnosed peripheral sensory polyneuropathy of different etiologies compared to placebo.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Procter and Gamble trials

Trials by the same sponsor.

NCT07158112 — Assessing Gingivitis and Plaque From a Marketed Toothpaste · Phase 4 · active not recruiting
NCT06962956 — Evaluating Gingivitis and Systemic Biomarkers · Phase 1 · active not recruiting
NCT06892834 — Assessing Gingivitis of 3 Different Dentifrices Compared to a Negative Control. · Phase 2 · completed
NCT06140784 — A Clinical Study to Assess the Gingivitis and Plaque Effects of Various Dentifrices · NA · completed
NCT06140758 — Evaluation of the Anticaries Efficacy of Dentifrice Formulations Using an In-situ Model · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05619328 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Procter and Gamble
Last refreshed: 28 November 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05619328.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing